Citations 46

Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal | August 6, 2024 | Volume: 30 | Issue: 10 | Pages: 1322-1330

10.1177/13524585241267231 | PMID 39105475

Background: Little is known about the relationship between neighborhood disadvantage and neuromyelitis optica spectrum disorder (NMOSD) outcomes. Objective: The objective is to determine the impact of neighborhood disadvantage on time from symptom onset to diagnosis and annualized relapse rate (ARR). Methods: Neighborhood disadvantage were captured with the Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage. Negative binomial regression models assessed the impact of ADI on diagnostic delay (⩾3 months between symptom onset and diagnosis) and ARR. Results: A total of 158 NMOSD patients were identified, a majority of whom were White (56.3%) and female (89.9%) with a mean age of 46 years at diagnosis. The ADI did not significantly affect odds of diagnostic delay (odds ratio (OR) = 0.99, p = 0.26). In univariable models, the ADI was not significantly associated with ARR (OR = 1.004, p = 0.29), but non-White race (OR = 1.541, p = 0.02) and time on immunosuppressive therapies (ISTs; OR = 0.994, p = 0.03) were. White patients used IST for an average of 81% of the follow-up period, compared to an average of 65% for non-White patients ( p < 0.01). Conclusion: No significant relationship between neighborhood-level disadvantage and diagnostic delay or ARR in NMOSD patients was observed. Non-White patients had a higher ARR, which may be related to less IST use.
Patient-reported Symptoms of Mood, Fatigue, and Sleep Are Not Captured by Clinician-reported Outcomes in Patients with LGI1-IgG Autoimmune Encephalitis (S4.002)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204582

The Spectrum of Inflammatory CNS Disorders Occurring During TNF-alpha Inhibitory Therapy (S11.002)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s11.002

Autoimmune encephalitis antibody biomarkers: Frequency, age and sex associations (1579)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1579

Adding FUEL to the FLAMES: FLAIR-variable Unilateral Enhancement of the Leptomeninges (FUEL) in MOG-IgG-Associated Disease (862)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.862

Frequency and Phenotype of Coexisting AQP4-IgG with Synaptic Autoantibodies in Patients Undergoing Serological Testing for CNS Inflammatory Disease (622)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.622

Do MOG-IgG+ Patients Fulfill the 2015 International Diagnostic Criteria for NMOSD? (5150)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.5150

Optic Chiasm Involvement Associated with Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies (4907)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4907

Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders (1906)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1906

Cerebral cortical encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (P16-1.002)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2497